Related Experiment Video

Updated: May 27, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?

Darren Aw1, Jagdish C Sharma

  • 1Department of Medicine for the Elderly, Lincoln County Hospital, Lincoln, UK. darren.aw@gmail.com

Postgraduate Medical Journal
|November 29, 2011
PubMed

Insights

Clopidogrel is an effective antiplatelet therapy for preventing recurrent strokes and vascular events. It shows comparable efficacy to aspirin and dipyridamole, with a better side effect profile.

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Antiplatelet therapy is crucial for secondary stroke prevention.
  • Non-cardioembolic ischemic stroke and ischemic heart disease share common pathophysiology.
  • Clopidogrel has demonstrated efficacy in preventing vascular events.

Purpose of the Study:

  • To evaluate clopidogrel's role in secondary prevention of non-cardioembolic ischemic stroke.
  • To compare clopidogrel's efficacy and safety with aspirin and aspirin/dipyridamole combinations.
  • To assess clopidogrel's potential use in transient ischemic attacks (TIAs).

Main Methods:

  • Review of recent evidence on antiplatelet therapies.
  • Comparison of clopidogrel with aspirin monotherapy and aspirin/extended-release dipyridamole combination therapy.
  • Extrapolation of findings to TIAs based on shared disease spectrum.

Main Results:

  • Clopidogrel is as effective as aspirin and extended-release dipyridamole for recurrent stroke prevention.
  • Clopidogrel is superior to aspirin monotherapy.
  • Clopidogrel exhibits a more favorable side effect profile than extended-release dipyridamole.

Conclusions:

  • Clopidogogrel is a viable first-line option for secondary prevention in non-cardioembolic stroke and TIAs.
  • Its efficacy across cerebrovascular and cardiac territories supports its use.
  • Clopidogrel offers a favorable balance of efficacy and safety for preventing recurrent ischemic events.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...